SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NNVC Keeping it real board for pro and con discussions
NNVC 1.660-1.2%3:36 PM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Savant who wrote (324)4/7/2020 8:58:57 PM
From: HardToFind1 Recommendation

Recommended By
Savant

  Read Replies (1) of 326
 
Favipiravir Caveats

en.wikipedia.org

In 2014, Japan approved Favipiravir for treating viral strains unresponsive to current antivirals. Toyama Chemical initially hoped that Favipiravir would become a new influenza drug that could replace Tamiflu. However, animal experiments show the potential for teratogenic effects on fetuses, and the approval of production by The Ministry of Health, Labor and Welfare was greatly delayed and the production condition is limited only in an emergency in Japan.

In March 2015, the US Food and Drug Administration completed a Phase III clinical trial studying the safety and efficacy of Favipiravir in the treatment of influenza.

On 15 March 2020 the drug was approved in China with the name Favilavir for the treatment of influenza. The drug was also approved for use in clinical trials for treating coronavirus disease 2019 pneumonia.

On 22 March 2020 Italy has approved the drug for experimental use against COVID-19 and has begun conducting trials in 3 regions most affected by the disease. The Italian Pharmaceutical Agency, however, has reminded the public that the existing evidence in support of this drug is scant and preliminary.

[This does seem like the ideal time to experiment with its use...a worldwide pandemic largely affecting elderly people (not of child-bearing age). God help us all...]
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News